American Society of Clinical Oncology 2011 CNS tumors update

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1495-1497

  Ahluwalia, Manmeet S ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; chemotherapy; glioblastoma; lymphoma; medulloblastoma; radiotherapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ENZASTAURIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; TEMOZOLOMIDE; VINCRISTINE;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CHEMORADIOTHERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; GLIOBLASTOMA; HUMAN; LYMPHOCYTOPENIA; LYMPHOMA; MEDICAL SOCIETY; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; GLIOBLASTOMA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80054719494     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.151     Document Type: Conference Paper

References (16)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
2. Bignami M, O'Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat. Res. 462(2-3), 71-82 (2000). (Pubitemid 30190215)
3. Dumenco LL, Warman B, Hatzoglou M, Lim IK, Abboud SL, Gerson SL. Increase in nitrosourea resistance in mammalian cells by retrovirally mediated gene transfer of bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res. 49(21), 6044-6051 (1989). (Pubitemid 19274168)
4. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). (Pubitemid 40349502)
5. Gilbert MR, Wang M, Aldape KD et al. RTOG 0525: a randomized Phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 29(Suppl. 15), 2006 (2011).
6. Aldape KD, Wang M, Sulman EP et al. RTOG 0525: molecular correlates from randomized Phase III trial of newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 29(Suppl. 15), LBA2000 (2011).
7. Tabatabai G, Frank B, Wick A et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann. Neurol. 61(2), 153-161 (2007). (Pubitemid 46363842)
8. Wick W, Steinbach J, Combs SE et al. Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled Phase II study. ASCO Meeting Abstracts 29(Suppl. 15), 2007 (2011).
9. Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J. Clin. Oncol. 24(36), 5711-5715 (2006). (Pubitemid 46631313)
10. Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a Phase 3, randomised, non-inferiority trial. Lancet Oncol. 11(11), 1036-1047 (2010).
11. Jahnke K, Korfel A, Martus P et al. Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized Phase III trial (G-PCNSL-SG-1). ASCO Meeting Abstracts 29(Suppl. 15), 2004 (2011).
12. Martus P, Jahnke K, Korfel A et al. Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: results from a German Phase III trial (G-PCNSL-SG-1). ASCO Meeting Abstracts 29(Suppl. 15), 2005 (2011)
13. CBTRUS. 1995-1999 Statistical Report: primary brain tumors in the United States. In: Central Brain Tumor Registry of the United States. CBTRUS, IL, USA (2002).
14. Packer RJ, Gajjar A, Vezina G et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 24(25), 4202-4208 (2006). (Pubitemid 46622300)
15. Dhall G, Grodman H, Ji L et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the 'Head Start' I and II protocols. Pediatr. Blood Cancer 50(6), 1169-1175 (2008). (Pubitemid 351555540)
16. Dhall G, Ji L, Haley K et al. Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol. ASCO Meeting Abstracts 29(Suppl. 15), (2011) Abstract 2011.